KIAA0146 inhibitors are a class of chemical compounds that target the protein KIAA0146, also known as ASXL3. This protein belongs to the ASXL (Additional Sex Combs-Like) family, which plays a significant role in chromatin modification and epigenetic regulation. KIAA0146 is involved in various cellular processes, including transcriptional regulation and the maintenance of gene expression profiles. By inhibiting the activity of this protein, KIAA0146 inhibitors can modulate these processes, impacting gene expression patterns and chromatin structure. The inhibition of KIAA0146 is particularly relevant for understanding how alterations in epigenetic regulators affect various signaling pathways, contributing to shifts in cellular function.
The mechanisms by which KIAA0146 inhibitors achieve their effects involve the disruption of protein-protein interactions and the alteration of post-translational modifications that are central to chromatin remodeling. These compounds are designed to interfere with specific domains of the KIAA0146 protein, such as the plant homeodomain (PHD) or other regions important for its interaction with histones and other chromatin-associated proteins. By binding to these domains, inhibitors prevent the proper assembly or function of protein complexes required for the regulation of chromatin dynamics. This, in turn, alters the chromatin landscape, potentially influencing cell differentiation, gene silencing, and other key biological processes that are tightly regulated by epigenetic mechanisms. The study of KIAA0146 inhibitors provides valuable insights into chromatin biology and the role of epigenetic factors in cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, a kinase involved in autophagy, potentially impacting pathways related to KIAA0146 function. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Specific inhibitor of vacuolar type H+-ATPase, affecting autophagy, relevant to KIAA0146's role. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Inhibits autophagy by preventing lysosome acidification, potentially impacting KIAA0146-related pathways. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Inhibits autophagy through PI3K inhibition, potentially affecting KIAA0146 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, known to affect autophagy and other signaling pathways, could impact KIAA0146. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor, potentially affecting autophagy and processes related to KIAA0146. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Promotes autophagy degradation, potentially affecting pathways involving KIAA0146. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Similar to Chloroquine, impacts lysosome function and autophagy, potentially affecting KIAA0146. | ||||||
Lys05 | 1391426-24-6 | sc-507532 | 5 mg | $140.00 | ||
Dual lysosomal inhibitor, more potent than chloroquine, could affect KIAA0146-related pathways. | ||||||
SAR405 | 1523406-39-4 | sc-507416 | 1 mg | $125.00 | ||
VPS34 inhibitor, could influence autophagy and pathways related to KIAA0146 function. | ||||||